Kestra Medical Technologies financials
$28.46+1.17%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jul 31 | Q4 '26 Apr 30 | Q3 '26 Jan 31 | Q2 '26 Oct 31 | Q1 '26 Jul 31 | Q4 '25 Apr 30 |
|---|---|---|---|---|---|---|
| Revenue | $31.0M | $28.6M | $24.6M | $22.6M | $19.4M | $17.2M |
| Gross profit | $17.5M | $15.7M | $12.9M | $11.4M | $8.9M | $7.6M |
| Gross margin | 56.5% | 54.8% | 52.6% | 50.6% | 45.7% | 44.3% |
| Operating income | -$37.7M | -$39.3M | -$34.8M | -$31.8M | -$28.9M | -$48.2M |
| Net income | -$44.1M | -$38.8M | -$34.2M | -$32.8M | -$25.8M | -$55.3M |
| Net margin | −142.3% | −135.6% | −139.2% | −145.3% | −133.3% | −321.2% |
| Diluted EPS | $-0.75 | $-0.67 | $-0.61 | $-0.64 | $-0.50 | $-1.43 |
| EBITDA | -$35.0M | -$37.0M | -$32.8M | -$29.4M | -$26.9M | -$46.4M |
| Operating cash flow | -$32.3M | -$18.7M | -$18.4M | -$18.3M | -$26.3M | -$24.1M |
| Free cash flow | -$40.6M | -$28.4M | -$28.2M | -$25.6M | -$34.4M | -$31.4M |
| Diluted shares | 58.6M | 58.2M | 55.8M | 51.4M | 51.3M | 38.7M |
Balance sheet
| Period end | Jul 31 | Apr 30 | Jan 31 | Oct 31 | Jul 31 | Apr 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $68.6M | $99.7M | $291.3M | $175.4M | $201.2M | $237.6M |
| Short-term investments | $130.4M | $96.7M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $72.5M | $42.6M | $42.3M | $41.9M | $41.5M | $41.1M |
| Total assets | $347.4M | $358.5M | $379.3M | $246.7M | $266.3M | $295.7M |
| Total liabilities | $125.0M | $98.8M | $91.4M | $82.6M | $82.1M | $90.3M |
| Shareholders' equity | $222.4M | $259.7M | $288.0M | $164.1M | $184.2M | $205.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology